FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

Links shared publicly online about this topic.

1,259
total visits

FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery

Baxter International Inc. and Nycomed today announced the U.S. Food and Drug Administration (FDA) approval of TachoSil (Absorbable Fibrin Sealant Patch) for use as an adjunct to hemostasis in cardiovascular surgery. TachoSil is the first and only adjunctive hemostatic agent available in the U.S. that combines a collagen patch with a coating of human coagulation factors.

View full resource at news-medical.net

Tags: Osteoporosis, Drug, FDA, Baxter International, Nycomed, Surgery

Most Recently Shared on April 7, 2010 at 7:39 am By:

News-Medical.Net

Osteoporosis News: FDA approves TachoSil adjunctive hemostatic agent for use in cardiovascular surgery: Baxter Int... http://bit.ly/cdhAiW

2 years ago...

Retweet

Favorite

Also Shared By:

News-Medical.Net

TachoSil approved as adjunctive hemostatic agent - ONA

oncologynurseadvisor.com — “Baxter International and Nycomed have announced that TachoSil (absorbable fibrin sealant patch) has been approved as an adjunct to hemostasis for use in cardiovascular surgery when control of bleeding by standard surgical techniques (eg, suture, ligature, or cautery) is ineffective or impractical.” View full resource at oncologynurseadvisor.com